Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh (AMGN34) Price & Analysis

Q: Is Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh overvalued?

According to Wall Street analysts Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Which hedge fund is a major shareholder of Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh?

Currently, no hedge funds are holding shares in BR:AMGN34

― Followers

AMGN34 Stock Chart & Stats

R$70.20

R$1.00(1.45%)

Sep 14, 2026

―

Day’s Range― - ―

52-Week RangeR$0.01 - R$84.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)201.00

Market Cap

R$1.05T

Enterprise ValueR$1.23M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)23066.7

Beta0.02

Next Earnings

Nov 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding540,632,000

10 Day Avg. Volume381

30 Day Avg. Volume201

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh News

Amgen to deploy Veeva Vault CRM globally

Veeva Systems (VEEV) announced that Amgen (AMGN) plans to deploy Veeva Vault CRM globally, building on a collaboration...

8h ago

AMGN

VEEV

Amgen says FDA approves update to imdelltra Prescribing Information

Amgen (AMGN) announced that the U.S. FDA approved an update to the imdelltra Prescribing Information that substantially reduces...

1d ago

AMGN

Meta upgraded, Nvidia initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

5d ago

HSBC downgrades Amgen to Hold on fair value after re-rating

HSBC analyst Morten Herholdt last night downgraded Amgen (AMGN) to Hold from Buy with a price target of...

5d ago

AMGN

Amgen downgraded to Hold from Buy at HSBC

HSBC downgraded Amgen (AMGN) to Hold from Buy with a price target of $425, down from $445. Published...

6d ago

AMGN

SpaceX initiated, Intel upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

7d ago

BBY

LMT

Amgen, AstraZeneca report Phase 3 DeLLphi-305 study met primary endpoint

Amgen (AMGN) announced results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified...

7d ago

AZN

AMGN

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI plus Amgen’s...

7d ago

AZN

AMGN

Amgen downgraded to Market Perform from Outperform at BMO Capital

BMO Capital downgraded Amgen (AMGN) to Market Perform from Outperform with an unchanged price target of $450. The...

7d ago

AMGN

Novartis pelacarsen miss ‘not great on the margin for’ Amgen, says UBS

After Novartis (NVS) announced pelacarsen missed its primary endpoint of reducing cardiovascular events in the Phase 3 HORIZON...

8d ago

NVS

AMGN

Imdelltra’s Phase III Success in ES-SCLC Underpins Matt Phipps’ Buy Rating on Amgen

William Blair analyst Matt Phipps has maintained their bullish stance on AMGN stock, giving a Buy rating today....

7d ago

AMGN

Entera is on the Cusp of the Trial That Could Unlock America’s Osteoporosis Drug Market (NASDAQ: ENTX)

WSW, NY, August 31st, 2026, FinanceWire The drugs that rebuild bone are locked inside a channel most patients...

15d ago

LLY

NVO

Terence Flynn Reaffirms Hold on Amgen as Strong Q2 Results and 2026 Guidance Boost Outlook, Price Target Raised from $333 to $351

Terence Flynn, an analyst from Morgan Stanley, assigned the Hold rating on Amgen. The associated price target was...

1M ago

AMGN

Analyst Maintains Buy on Amgen After Strong Q2 Beat, Raised Guidance and Multiple Late-Stage Pipeline Catalysts

William Blair analyst Matt Phipps has reiterated their bullish stance on AMGN stock, giving a Buy rating yesterday....

1M ago

AMGN

AMGN34 FAQ

What was Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s price range in the past 12 months?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh lowest stock price was R$0.01 and its highest was R$84.00 in the past 12 months.

What is Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s market cap?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s market cap is R$1.05T.

When is Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s upcoming earnings report date?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s upcoming earnings report date is Nov 03, 2026 which is in 49 days.

How were Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s earnings last quarter?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh released its earnings results on Aug 04, 2026. The company reported R$0.001 earnings per share for the quarter.

Is Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh overvalued?

According to Wall Street analysts Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh pay dividends?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh does not currently pay dividends.

What is Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s EPS estimate?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh have?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh has 540,632,000 shares outstanding.

What happened to Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s price movement after its last earnings report?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh reported an EPS of R$0.001 in its last earnings report. Following the earnings report the stock price went up 4.322%.

Which hedge fund is a major shareholder of Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh?

Currently, no hedge funds are holding shares in BR:AMGN34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology